Daunomycin in the treatment of experimental proliferative vitreoretinopathy. Effective doses in vitro and in vivo

• Published in: Investigative ophthalmology & visual science Vol. 26; no. 5; pp. 719 - 725
• Main Authors: Wiedemann, P, Sorgente, N, Bekhor, C, Patterson, R, Tran, T, Ryan, SJ
• Format: Journal Article
• Language: English
• Published: United States ARVO 01-05-1985
• Subjects: Animals; Autoradiography; Chromatography, High Pressure Liquid; Daunorubicin - administration & dosage; Daunorubicin - analysis; Daunorubicin - therapeutic use; Eye Diseases - drug therapy; Eye Diseases - metabolism; Fibroblasts - drug effects; In Vitro Techniques; Rabbits; Retinal Diseases - drug therapy; Retinal Diseases - metabolism; Spectrometry, Fluorescence; Vitreous Body - analysis
• ISSN: 0146-0404; 1552-5783

In previous studies the authors have shown that daunomycin, an anthracycline antibiotic, when injected into the vitreous effectively controls experimental proliferative vitreoretinopathy. Here we show that by administering daunomycin intravitreally it is possible to achieve in vivo concentrations that prevent fibroblast proliferation in vitro. The authors have also determined that the half-life of daunomycin in the vitreous is 131 min, indicating that a critical concentration is maintained in the eye for longer than 4 hr after a single injection. Using 3H-daunomycin, the authors have found that the drug is eliminated across the retina; no significant binding of the drug to vitreous components occurs. These studies demonstrate that it is possible to define the kinetics of drugs injected into the vitreous; and a knowledge of the distribution of any drug in ocular tissues is necessary to effectively determine whether such drug is of therapeutic value.